A promising multitarget approach for treating metabolic diseases by combining peripheral PPARδ‐mediated activity with the hepatic effects of FXR activation was proposed by Schierle et al. (2020).[90] They designed a minimal dual FXR/PPARδ activator scaffold by rationally merging pharmacophores from existing selective agonists. Here, NR1H4 is linked to Other metabolic disease.